«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 19

Page:

3763-3768

Research Field:

Publishing date:

Info

Title:

Cases report and clinical analysis of uterine intravascular leiomyoma

Author(s):

LIU Ying¹; PAN Hanmei²; WANG Hongyan³; LIAO Xingya³; YANG Linlin¹

1.Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center,Yunnan Kunming 650118,China;2.Northeast Yunnan Regional Central Hospital,Yunnan Zhaotong 657000,China;3.Kunming Medical University,Yunnan Kunming 650500,China.

Keywords:

uterine intravascular leiomyomatosis; invasion of the heart; misdiagnosis; diagnosis and treatment

PACS:

R737.3

DOI:

10.3969/j.issn.1672-4992.2024.19.024

Abstract:

Objective:By analyzing the clinical data of endovascular leiomyoma［also called intravenous leiomyoma(IVL)］,we can understand the core characteristics of this disease to guide the clinic.Methods:Focus on the 2 cases identified in a short period of time，we retrospectively analyzed 12 patients diagnosed with IVL in our hospital.We combined the relevant literature,the incidence,age of onset,high-risk population,diagnosis,treatment,prognosis and follow-up of this rare disease were comprehensively analyzed and discussed.Results:Including the two cases,a total of 12 patients with IVL were admitted to our hospital,aged from 42 to 55 years.We combined the high-risk population,clinical symptoms,imaging examinations,surgical conditions,prognosis and follow-up of this rare disease were comprehensively analyzed and discussed.Conclusion:IVL mainly occurs in premenopausal women,and all of them are complicated with hysteromyoma.It is difficult to make a definite diagnosis before operation.Intravascular tumor thrombus spread along the branches of the blood vessels,independent of the direction of venous return.Surgery is the most direct and effective treatment for IVL.The recurrence of IVL is closely related to whether there is residual disease after surgery.For patients with ovarian preservation,endocrine therapy is an option,but the suitable population,duration of treatment,and efficacy of endocrine therapy are still controversial.

References:

［1］LI H,XU J,LIN Q,et al.Surgical treatment strategies for extra-pelvic intravenous leiomyomatosis［J］.Orphanet J Rare Dis,2020,15(1):153.
［2］YANO M,KATOH T,NAKAJIMA Y,et al.Uterine intravenous leiomyomatosis with an isolated large metastasis to the right atrium:A case report［J］.Diagn Pathol,2020,15(1):4.
［3］中国医师协会妇产科医师分会妇科肿瘤学组.盆腔静脉内平滑肌瘤病临床诊治中国专家共识［J］.中华妇产科杂志,2023,58(4):252-258. Gynecologic Oncology Group,Society of Obstetricians and Gynecologists,Chinese Medical Doctor Association.Chinese expert consensus on the clinical diagnosis and treatment of pelvic intravenous leiomyomatosis［J］.Chin J Obstetrics and Gynecology,2023,58(4):252-258.
［4］J SIMON WR，PARRY－SMITH CWE，REDMAN M,et al.Intravascular leiomyomatosis:A case report and review of the literature［J］.J Obst Gynaecol,2014,19:1-2．
［5］卢朝辉，陈杰.WHO女性生殖器官肿瘤学分类(第4 版) 解读［J］.中华病理学杂志，2014，43(10):649－650. LU ZH,CHE J.The WHO classification of female reproductive organs oncology(fourth edition)［J］.Chinese Journal of Pathology,2014,43(10):649-650.
［6］沈丹华，陈定宝.解读第4 版WHO 女性生殖器官肿瘤分类中的变化［J］.中华妇产科杂志,2014,49(9):717-720. SHEN DH,CHEN DB.Reading version 4 WHO changes in female reproductive organs tumor classification［J］.Chinese Journal of Obstetrics and Gynecology,2014,49(9):717-720.
［7］ORDULU Z，NUCCI MR，DAL CIN P，et al.Intravenous leiomyomatosis:An unusual intermediate between benign and malignant uterine smoothmuscle tumors［J］.Mod Pathol,2016,29(5):500-510.
［8］CASTAGNETO GISSEY L,MARIANO G,MUSLEH L,et al.Massive pelvic recurrence of uterine leiomyomatosis with intracaval-intracardiac extension:Video case report and literature review［J］.BMC Surg,2017,17(1):118.
［9］GRUZ I，JOAO I，STUART B,et al.Intravenous leiomyomatosis:A rare case of intracardiac mass［J］.RVE Port Cardiol,2014,33:735-740．
［10］NATANSON K,LI II.Zur anatomie und entwicklungsgeschichte des uterus unicornis(Part 1 of 2)［J］.Gynecologic & Obstetric Investigation,1904,20(6):1195-1206.
［11］RADSWIKI T,KNIPE H,LEONG Y,et al.Intravenous leiomyomatosis［EB/OL］.［2024-03-19］.https://doi.org/10.53347/rID-13103.
［12］DAL CP,QUADE BJ,NESKEY DM,et al.Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(q15;q24)［J］.Genes Chromosomes Cancer,2003,36(2):205-206.
［13］BUZA N,XU F,WU W,et al.Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus:High-resolution array comparative genomic hybridization study［J］.Hum Pathol,2014,45:1885-1892.
［14］YAGUCHI C,OI H,KOBAYASHI H,et al.A case of intravenous leiomyomatosis with high levels of hyaluronan［J］.J Obstet Gynaecol Res,2010,36:454-458.
［15］徐婷，胡君，朱丽荣.子宫静脉内平滑肌瘤病4例并文献复习［J］.现代肿瘤医学，2018,26（14）：2275-2278. XU T,HU J,ZHU LR.Intravenous leiomyomatosis of the uterus:A report of 4 cases and review of the literature［J］.Modern Oncology，2018,26（14）：2275-2278.
［16］NAM MS,JEON MJ,KIM YT,et al.Pelvic leiomyomatosis with intracaval and intracardiac extension:A case report and review of the literature［J］.Gynecol Oncol 2003,89:175-180.
［17］QIUYING L,CHENGFENG H,XIAOSHEN Z.et al.Intravenous leiomyomatosis extending into right heart:A case report［J］.Turk Gogus Kalp Damar Cerrahisi Derg,2020,28(2):386-389.
［18］BRUNEL I,IACOPONI S,HERNANDEZ A,et al.Intravascular leiomyomatosis:An exceptional entity［J］.Clin Exp Obstet Gynecol,2016,43(3):443-445.
［19］谢江平，张朝军.累及下腔静脉及右心的静脉内平滑肌瘤病的外科治疗-附2例报道［J］.现代肿瘤医学，2017，25（9）：1466-1469. XIE JP,ZHANG CJ.Surgical therapy of intravenous leiomyomatosis with intracaval and intracardiac extension in 2 cases［J］.Modern Oncology，2017，25（9）：1466-1469.
［20］张明光,桂欣钰,马国涛,等.静脉内平滑肌瘤病一例［J］.协和医学杂志,2016,7(3):235-237. ZHANG GM,GUI XY,MA GT,et al.Intravenous leiomyomatosis:A case report［J］.Union Medical Journal,2016,7(3):235-237.
［21］KOMMOSS F,EBEL T,DRUSENHEIMER J,et al.Die intravenose leiomyomatose［Intravenous leiomyomatosis］［J］.Pathologe,2019,40(1):80-84.
［22］MATHEY MP,DUC C,HUBER D.et al.Intravenous leiomyomatosis:Case series and review of the literature［J］.Int J Surg Case Rep,2021,85:106257.
［23］CHOU CY,CHEN CH.Pelvic intravenous leiomyomatosis［J］.AJOG Glob Rep,2023,3(4):100287.
［24］MITSUHASHI A,NAGAI Y,SUGUTA M,et al.GnRH agonist for intravenous leiomyomatosis with cardiac extension.A case report［J］.J Reprod Med,1999,44:883-886.
［25］MIZOGUCHI C,MATSUMOTO H,NASU K,et al.Intravenous leiomyomatosis treated with radical hysterectomy and adjuvant aromatase inhibitor therapy［J］.J Obstet Gynaecol Res,2016,42:1405-1408.
［26］KOKAWA K，YAMOTO M，YATA C，et al.Postmenopausal intravenous leiomyomatosis with high levels of estradiol and estrogen receptor［J］.Obstet Gynecol,2002,100:1124-1126．
［27］LI B，WU LY，MA SK，et al．Intravenous leiomyomatosis of the uterus:A report of 3 cases and review of the literatures［J］.Chin J Clin Oncol,2005,32(18):1058-1060．
［28］冯慧琳，张丹晔，朱秀明，等.血管内平滑肌瘤病21例临床分析［J］.现代肿瘤医学,2016,24(9):1433－1438. FENG HL,ZHANG DY,ZHU XM,et al.A clinical analysis of 21 intravascular leiomyomatosis cases［J］.Modern Oncology,2016,24(9):1433－1438.
［29］BODNER K，BODNER-ADLER B，WIERRANI F，et al．Intravenous leiomyomatosis of the uterus［J］.Anticancer Res,2002,22:1881-1883．
［30］NISHIZAWA J，MATSUMOTO M，SUGITA T,et al.Intravenous leiomyomatosis extending into the righy ventricle associated with pulmonary metastasis and extensive arteriovenous fistula［J］.J Am Coll Surg,2004,198:842-843．
［31］WU K，WEI LH.Clinical analysis of intravenous leiomyomatosis:Report of 9 cases［J］.Chin J Cancer Prev Treat,2009,16:704-706．
［32］LIU N,LONG Y,LIU Y.et al.Intravenous leiomyomatosis:Case series and review of the literature［J］.J Int Med Res,2020,48(1):300060519896887.

Memo

Memo:

云南省教育厅科学研究基金项目（编号：2024J0264）;云南省科技厅—昆明医科大学联合专项（编号：202001AY070001-243）

Common functions

Last Update: 2024-08-30